Herombopag
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Immune Thrombocytopenia
Conditions
Immune Thrombocytopenia
Trial Timeline
Jan 23, 2023 → Jun 30, 2024
NCT ID
NCT05685420About Herombopag
Herombopag is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Immune Thrombocytopenia. The current trial status is unknown. This product is registered under clinical trial identifier NCT05685420. Target conditions include Immune Thrombocytopenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05685420 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Immune Thrombocytopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Placebo + Lusutrombopag | Shionogi | Phase 2 | 52 |
| Lusutrombopag | Shionogi | Phase 2 | 52 |
| Romiplostim | Kyowa Kirin | Phase 1/2 | 41 |
| AMG 531 | Kyowa Kirin | Phase 2/3 | 65 |
| Romiplostim + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Romiplostim (AMG-531) | Kyowa Kirin | Phase 2 | 52 |
| Romiplostim and danazol | Kyowa Kirin | Phase 2 | 52 |
| Hetrombopag Olamine | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Zostavax® | Merck | Pre-clinical | 23 |
| Raltegravir + Atazanavir | Merck | Pre-clinical | 23 |
| Zostavax | Merck | Pre-clinical | 23 |
| MK-8723 + Matching Placebo | Merck | Phase 1 | 33 |
| Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM | Novartis | Phase 2 | 52 |